糖尿病肾病治疗潜在靶点胰高血糖素样肽-1受体  

A potential target for the treatment of diabetic nephropathy:glucagon-like peptide-1 receptor

作　　者：徐媛颖 蔡兴华 张会会 孔稳稳 沙雯君 雷涛[1] XU Yuanying;CAI Xinghua;ZHANG Huihui;KONG Wenwen;SHA Wenjun;LEI Tao(Department of Endocrinology,Putuo Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200062,China;School of Clinical Medicine,Shanghai Putuo Center Affiliated to Anhui Medical University,Shanghai 200062,China;School of Clinical Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China)

机构地区：[1]上海中医药大学附属普陀医院内分泌科,上海200062 [2]安徽医科大学上海普陀中心临床医学院,上海200062 [3]成都中医药大学临床医学院,四川成都610075

出　　处：《世界临床药物》2023年第9期899-903,共5页World Clinical Drug

基　　金：上海市医学重点专科(ZK2019B16);上海市卫生健康委员会科研课题(20204Y0154);上海市卫健委课题(202240309);上海市普陀区临床特色专科(2020tszk01);上海市普陀区卫生健康系统科技创新项目(ptkwws202003)。

摘　　要：糖尿病肾病(diabetic nephropathy,DN)致病机制复杂,涉及代谢、血流动力学及炎症等方面。目前,DN主要治疗药物为肾素-血管紧张素系统抑制剂,但非所有患者都可获得满意疗效。胰高血糖素样肽-1受体(glucagon-like peptide-1receptor,GLP-1R)作为一种治疗DN的潜在靶点,其在调节血糖稳态和心血管保护方面益处较大,对降低DN相关肾脏不良结局发生风险具有潜在作用。现概述GLP-1R作为治疗DN靶点在缓解疾病进展方面的作用机制,探讨相关制剂在临床应用中的疗效。The pathogenesis of diabetic nephropathy(DN)is complex,involving metabolism,hemodynamics and inflammation.At present,the main treatment drugs for DN are renin-angiotensin system inhibitors,but not all patients can obtain satisfactory results.Glucagon-like peptide-1 receptor(GLP-1R),as a potential target for the treatment of DN,has great benefits in regulating blood glucose homeostasis and cardiovascular protection,and has a potential role in reducing the risk of renal adverse outcomes related to DN.This article reviewed the mechanism of GLP-1R as a therapeutic target for DN in alleviating disease progression,and discusses the efficacy of related preparations in clinical application.

关 键 词：糖尿病肾病 胰高血糖素样肽-1受体 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌] R692.9[医药卫生—内科学]